The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Childhood brain tumors: current management, biological insights, and future directions: JNSPG 75th Anniversary Invited Review Article
Open accessAbstract
Brain tumors are the most common solid tumors in children, and, unfortunately, many subtypes continue to have a suboptimal long-term outcome. During the last several years, however, remarkable advances in our understanding of the molecular underpinnings of these tumors have occurred as a result of high-resolution genomic, epigenetic, and transcriptomic profiling, which have provided insights for improved tumor categorization and molecularly directed therapies. While tumors such as medulloblastomas have been historically grouped into standard- and high-risk categories, it is now recognized that these tumors encompass four or more molecular subsets with distinct clinical and molecular characteristics. Likewise, high-grade glioma, which for decades was considered a single high-risk entity, is now known to comprise multiple subsets of tumors that differ in terms of patient age, tumor location, and prognosis. The situation is even more complex for ependymoma, for which at least nine subsets of tumors have been described. Conversely, the majority of pilocytic astrocytomas appear to result from genetic changes that alter a single, therapeutically targetable molecular pathway. Accordingly, the present era is one in which treatment is evolving from the historical standard of radiation and conventional chemotherapy to a more nuanced approach in which these modalities are applied in a risk-adapted framework and molecularly targeted therapies are implemented to augment or, in some cases, replace conventional therapy. Herein, the authors review advances in the categorization and treatment of several of the more common pediatric brain tumors and discuss current and future directions in tumor management that hold significant promise for patients with these challenging tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 2×
“37,62 One landmark observation was the detection of novel mutations in histones H3F3A (positions K27 and G34) and HIST1H3B (position K27).”
BackgroundMackay, A., Burford, A., Carvalho, D., Izquierdo, E., Fazal-Salom, J., Taylor, K. R., Bjerke, L., Clarke, M., Vinci, M., Nandhabalan, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.017 · Cited by 1,212
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Packer, R. J., Gajjar, A., Vezina, G., Rorke-Adams, L., Burger, P. C., Robertson, P. L., Bayer, L., LaFond, D., Donahue, B. R., Marymont, M. H., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4980 · Cited by 989
Gajjar, A., Chintagumpala, M., Ashley, D., Kellie, S., Kun, L. E., Merchant, T. E., Woo, S., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Self-citationJones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Duffner, P. K., Horowitz, M. E., Krischer, J. P., Friedman, H. S., Burger, P. C., Cohen, M. E., Sanford, R. A., Mulhern, R. K., James, H. E., Freeman, C. R., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282401 · Cited by 841
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone
Rutkowski, S., Bode, U., Deinlein, F., Ottensmeier, H., Warmuth-Metz, M., Soerensen, N., Graf, N., Emser, A., Pietsch, T., Wolff, J. E. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042176 · Cited by 751
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N. E., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E. C., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3855 · Cited by 687
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S. C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1569-6 · Cited by 654
Pollack, I. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312207 · Cited by 556
Self-citationPaediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555 · cited 3×
“28,67 Genome-wide methylation profil - ing suggested the existence of six epigenetically distinct subgroups of glioblastoma that include pediatric patients.”
Ostrom, Q. T., de Blank, P. M., Kruchko, C., Petersen, C. M., Liao, P., Finlay, J. L., Stearns, D. S., Wolff, J. E., Wolinsky, Y., Letterio, J. J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou327 · Cited by 552
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Pfister, S., Janzarik, W. G., Remke, M., Ernst, A., Werft, W., Becker, N., Toedt, G., Wittmann, A., Kratz, C., Olbrich, H., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33656 · Cited by 523
Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study
Merchant, T. E., Li, C., Xiong, X., Kun, L. E., Boop, F. A., & Sanford, R. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70342-5 · Cited by 510
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma
Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D. J. H., Martin, D. C., Castelo-Branco, P., Baskin, B., Ray, P. N., Bouffet, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5052 · Cited by 485
Self-citationRobinson, G. W., Orr, B. A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I., Packer, R. J., Goldman, S., Prados, M. D., Desjardins, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1591 · Cited by 448
Ellison, D. W., Onilude, O. E., Lindsey, J. C., Lusher, M. E., Weston, C. L., Taylor, R. E., Pearson, A. D., & Clifford, S. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5479 · Cited by 435
Ater, J. L., Zhou, T., Holmes, E., Mazewski, C. M., Booth, T. N., Freyer, D. R., Lazarus, K. H., Packer, R. J., Prados, M., Sposto, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.6054 · Cited by 433
Self-citationCohen, K. J., Pollack, I. F., Zhou, T., Buxton, A., Holmes, E. J., Burger, P. C., Brat, D. J., Rosenblum, M. K., Hamilton, R. L., Lavey, R. S., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq191 · Cited by 399
Self-citationFinlay, J. L., Boyett, J. M., Yates, A. J., Wisoff, J. H., Milstein, J. M., Geyer, J. R., Bertolone, S. J., McGuire, P., Cherlow, J. M., & Tefft, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.112 · Cited by 366
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype
Phoenix, T. N., Patmore, D. M., Boop, S., Boulos, N., Jacus, M. O., Patel, Y. T., Roussel, M. F., Finkelstein, D., Goumnerova, L., Perreault, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.002 · Cited by 353
Korshunov, A., Ryzhova, M., Hovestadt, V., Bender, S., Sturm, D., Capper, D., Meyer, J., Schrimpf, D., Kool, M., Northcott, P. A., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1405-4 · Cited by 350
Pajtler, K. W., Mack, S. C., Ramaswamy, V., Smith, C. A., Witt, H., Smith, A., Hansford, J. R., von Hoff, K., Wright, K. D., Hwang, E., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1643-0 · Cited by 337
Cohen, K. J., Heideman, R. L., Zhou, T., Holmes, E. J., Lavey, R. S., Bouffet, E., & Pollack, I. F. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq205 · Cited by 331
Self-citationBanerjee, A., Jakacki, R. I., Onar-Thomas, A., Wu, S., Nicolaides, T., Young Poussaint, T., Fangusaro, J., Phillips, J., Perry, A., Turner, D., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now282 · Cited by 319
Self-citationCytogenetic Prognostication Within Medulloblastoma Subgroups
Shih, D. J. H., Northcott, P. A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9539 · Cited by 313
Self-citationZarghooni, M., Bartels, U., Lee, E., Buczkowicz, P., Morrison, A., Huang, A., Bouffet, E., & Hawkins, C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5463 · Cited by 313
Souweidane, M. M., Kramer, K., Pandit-Taskar, N., Zhou, Z., Haque, S., Zanzonico, P., Carrasquillo, J. A., Lyashchenko, S. K., Thakur, S. B., Donzelli, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30322-x · Cited by 267
Palmer, S. L., Armstrong, C., Onar-Thomas, A., Wu, S., Wallace, D., Bonner, M. J., Schreiber, J., Swain, M., Chapieski, L., Mabbott, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4775 · Cited by 240
Robinson, G. W., Rudneva, V. A., Buchhalter, I., Billups, C. A., Waszak, S. M., Smith, K. S., Bowers, D. C., Bendel, A., Fisher, P. G., Partap, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30204-3 · Cited by 234
Walter, A. W., Mulhern, R. K., Gajjar, A., Heideman, R. L., Reardon, D., Sanford, R. A., Xiong, X., & Kun, L. E. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3720 · Cited by 225
Chheda, Z. S., Kohanbash, G., Okada, K., Jahan, N., Sidney, J., Pecoraro, M., Yang, X., Carrera, D. A., Downey, K. M., Shrivastav, S., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171046 · Cited by 214
Self-citationEverolimus long-term safety and efficacy in subependymal giant cell astrocytoma
Krueger, D. A., Care, M. M., Agricola, K., Tudor, C., Mays, M., & Franz, D. N. (2013) · Neurology · doi:10.1212/wnl.0b013e3182815428 · Cited by 210
Laughton, S. J., Merchant, T. E., Sklar, C. A., Kun, L. E., Fouladi, M., Broniscer, A., Morris, E. B., Sanders, R. P., Krasin, M. J., Shelso, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.13.5293 · Cited by 209
Self-citationvon Bueren, A. O., von Hoff, K., Pietsch, T., Gerber, N. U., Warmuth-Metz, M., Deinlein, F., Zwiener, I., Faldum, A., Fleischhack, G., Benesch, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor025 · Cited by 188
von Bueren, A. O., Kortmann, R.-D., von Hoff, K., Friedrich, C., Mynarek, M., Müller, K., Goschzik, T., zur Mühlen, A., Gerber, N., Warmuth-Metz, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2428 · Cited by 188
for the Children’s Oncology Group, Pollack, I. F., Hamilton, R. L., Sobol, R. W., Nikiforova, M. N., Lyons-Weiler, M. A., LaFramboise, W. A., Burger, P. C., Brat, D. J., Rosenblum, M. K., et al. (2011) · Child's Nervous System · doi:10.1007/s00381-010-1264-1 · Cited by 185
Self-citationJakacki, R. I., Cohen, K. J., Buxton, A., Krailo, M. D., Burger, P. C., Rosenblum, M. K., Brat, D. J., Hamilton, R. L., Eckel, S. P., Zhou, T., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now038 · Cited by 182
Self-citationFreeman, C. R., Krischer, J. P., Sanford, R. A., Cohen, M. E., Burger, P. C., del Carpio, R., Halperin, E. C., Munoz, L., Friedman, H. S., & Kun, L. E. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90228-n · Cited by 175
Kieran, M. W., Chisholm, J., Casanova, M., Brandes, A. A., Aerts, I., Bouffet, E., Bailey, S., Leary, S., MacDonald, T. J., Mechinaud, F., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox109 · Cited by 175
Pollack, I. F., Hamilton, R. L., Sobol, R. W., Burnham, J., Yates, A. J., Holmes, E. J., Zhou, T., & Finlay, J. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.7265 · Cited by 173
Self-citationPemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma
Morfouace, M., Shelat, A. A., Jacus, M. O., Freeman, B. B., Turner, D. C., Robinson, S., Zindy, F., Wang, Y., Finkelstein, D., Ayrault, O., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.009 · Cited by 171
Gururangan, S., Fangusaro, J., Poussaint, T. Y., McLendon, R. E., Onar-Thomas, A., Wu, S., Packer, R. J., Banerjee, A., Gilbertson, R. J., Fahey, F., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not154 · Cited by 163
Self-citationMerchant, T. E., Rose, S. R., Bosley, C., Wu, S., Xiong, X., & Lustig, R. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9453 · Cited by 162
Grill, J., Massimino, M., Bouffet, É., Azizi, A. A., McCowage, G. B., Cañete, A., Saran, F. H., Deley, M. L., Varlet, P., Morgan, P. S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0611 · Cited by 153
Predicting Change in Academic Abilities After Conformal Radiation Therapy for Localized Ependymoma
Conklin, H. M., Li, C., Xiong, X., Ogg, R. J., & Merchant, T. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9970 · Cited by 145
Robinson, G. W., Kaste, S. C., Chemaitilly, W., Bowers, D. C., Laughton, S. J., Smith, A., Gottardo, N. G., Partap, S., Bendel, A. E., Wright, K. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20619 · Cited by 144
Pollack, I. F., Stewart, C. F., Koçak, M., Poussaint, T. Y., Broniscer, A., Banerjee, A., Douglas, J. G., Kun, L. E., Boyett, J. M., & Geyer, J. R. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq199 · Cited by 131
Self-citationLafay‐Cousin, L., Smith, A., Chi, S. N., Wells, E. M., Madden, J. R., Margol, A., Ramaswamy, V., Finlay, J. L., Taylor, M. D., Dhall, G., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26042 · Cited by 131
Garvin, J. H., Selch, M. T., Holmes, E., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24274 · Cited by 123
Bradley, K. A., Pollack, I. F., Reid, J. M., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-043 · Cited by 66
Self-citationRapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors
Lam, C. G., Bouffet, É., Tabori, U. Y., Mabbott, D., Taylor, M. D., & Bartels, U. K. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22298 · Cited by 61
Cited by
Ostrom, Q. T., Price, M., Ryan, K., Edelson, J., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac161 · Cited by 321
Metadata
- Authors
- Pollack, I. F., Agnihotri, S., & Broniscer, A.
- Venue
- Journal of Neurosurgery: Pediatrics
- Published
- 2019-03
- Volume
- 23
- Issue
- 3
- Pages
- 261-273
- ISSN
- 1933-0707 (ISSN-L)
- 1933-0715
- OpenAlex
- W2930687275
- Cited by
- 314
- References
- 59
- FWCI
- 15.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.